**Name of Journal**: *World Journal of Hepatology*

**Manuscript Type**: 43256

**Manuscript Type**: ORIGINAL ARTICLE

***Basic Study***

**Protective action of glutamine in rats with severe acute liver failure**

Schemitt EG *et al*. Glutamine is protective in severe ALF

Elizângela G Schemitt, Renata M Hartmann, Josieli R Colares, Francielli Licks, Jéferson O Salvi, Cláudio A Marroni, Norma P Marroni

**Elizângela G Schemitt, Renata M Hartmann, Josieli R Colares, Francielli Licks, Jéferson O Salvi, Cláudio A Marroni, Norma P Marroni**, Laboratory of Experimental Hepatology and Gastroenterology, Hospital de Clínicas de Porto Alegre, Porto Alegre 90040060, Brazil

**Elizângela G Schemitt, Renata M Hartmann, Josieli R Colares, Francielli Licks, Jéferson O Salvi, Norma P Marroni**, Laboratory of Oxidative Stress and Antioxidants, Universidade Luterana do Brasil, Canoas 92425900, Brazil

**ORCID number**: Elizângela G Schemitt (0000-0003-3015-0192); Renata M Hartmann (0000-0001-8667-517X); Josieli R Colares (0000-0002-0482-204X); Francielli Licks (0000-0002-3668-5879); Jéferson O Salvi (0000-0003-0954-412X); Cláudio A Marroni (0000-0002-1718-6548); Norma P Marroni (0000-0001-7856-7953).

**Author contributions**: Schemitt EG, Hartmann RM, Colares JR and Marroni NP contributed to study conception and design; Schemitt EG, Hartmann RM, Colares JR, Licks F and Salvi JO contributed to data acquisition, data analysis and interpretation, and writing of article; Schemitt EG, Marrini CA and Marroni NP contributed to editing and reviewing of article; all authors have read and approved of the final version of the article.

**Supported by** FIPE/Hospital de Clínicas of Porto Alegre.

**Institutional review board statement**: This study was conducted at the Animal Experimentation Unit and the Laboratory of Experimental Hepatology and Gastroenterology, Hospital de Clínicas of Porto Alegre, after approval from the Institutional Animal Care and Use Committee, No. CEUA 15-0175.

**Conflict-of-interest statement**: The authors have no conflicts of interest to disclose.

**ARRIVE guidelines statement**: The authors followed the ARRIVE checklist.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author**: **Claudio A Marroni, PhD, Professor**, Laboratory of Experimental Hepatology and Gastroenterology, Hospital de Clínicas de Porto Alegre, Rua José Kanan Aranha 102, Porto Alegre 90040060, Brazil. nmarroni@terra.com.br

**Telephone:** +55-51-999638306

**Received:** October 30, 2018

**Peer-review started:** October 30, 2018

**First decision:** December 21, 2018

**Revised:** January 29, 2019

**Accepted:** March 12, 2019

**Article in press:** March 12, 2019

**Published online:** March 27, 2019

**Abstract**

***BACKGROUND***

Severe acute liver failure (SALF) is a rare, but high-mortality, rapidly evolving syndrome that leads to hepatocyte degeneration with impaired liver function. Thioacetamide (TAA) is a known xenobiotic, which promotes the increase of the formation of reactive oxygen species. Erythroid 2-related factor 2 (Nrf2) activates the antioxidant protection of cells. Studies have evidenced the involvement of inflammatory mediators in conditions of oxidative stress.

***AIM***

To evaluate the antioxidant effects of glutamine on Nrf2 activation and NFκB-mediated inflammation in rats with TAA-induced IHAG.

***METHODS***

Male Wistar rats (*n* = 28) were divided into four groups: control, control+glutamine, TAA, and TAA + glutamine. Two TAA doses (400 mg/kg) were administered intraperitoneally, 8 h apart. Glutamine (25 mg/kg) was administered at 30 min, 24 h, and 36 h. At 48 h, blood was collected for liver integrity analysis [aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)]. The liver was harvested for histology and assessment of oxidative stress [thiobarbituric acid-reactive substances (TBARS), catalase (CAT), glutathione peroxidase (GPx), glutathione S-transferase (GST), glutathione (GSH), Nrf2, Kelch-like ECH-associated protein 1 (Keap1), NADPH quinone oxidoreductase1 (NQO1), superoxide dismutase (SOD)] and inflammatory process.

***RESULTS***

TAA caused disruption of the hepatic parenchyma, with inflammatory infiltration, massive necrosis, and ballooning degeneration. Glutamine mitigated this tissue damage, with visible regeneration of hepatic parenchyma; decreased TBARS (*P <* 0.001), GSH (*P <* 0.01), IL-1β, IL6, and TNFα levels (*P <*0.01) in hepatic tissue; and decreased blood levels of AST, ALT, and ALP (*P <*0.05). In addition, CAT, GPx, and GST activities were restored in the glutamine group (*P <*0.01, *P <*0.01, and *P <*0.001, respectively *vs* TAA alone). Glutamine increased expression of Nrf2 (*P <* 0.05), NQO1, and SOD (*P <* 0.01), as well as levels of IL-10 (*P <*0.001), while decreasing expression of Keap1, TLR4, NFκB (*P <* 0.001), COX-2 and iNOS, (*P <* 0.01), and reducing NO2 and NO3 levels (*P <* 0.05).

***CONCLUSION***

In the TAA experimental model of IHAG, glutamine activated the Nrf2 pathway, thus promoting antioxidant protection, and blunted the NFκB-mediated pathway, reducing inflammation.

**Key words**: Thioacetamide; Cytokines; Oxidative stress; Inflammation; Liver failure; Chemical and drug induced liver injury; Glutamine

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: Severe acute liver failure (SALF) is a rare syndrome characterized by rapid deterioration of liver function, usually in patients without underlying liver disease; the only effective treatment is transplantation. In this study, we used thioacetamide (TAA), a known xenobiotic hepatotoxicant, to induce SALF in rats. This was followed by administration of glutamine in an attempt to activate antioxidative defenses *via* the erythroid 2-related factor 2 (Nrf2) pathway and mitigate liver injury. Glutamine successfully activated Nrf2 and inhibited TLR4/NFκB-mediated inflammation, allowing restoration of parenchymal architecture and recovery of several parameters to near-control levels.

Schemitt EG, Hartmann RM, Colares JR, Licks F, Salvi JO, Marroni CA, Marroni NP. Protective action of glutamine in rats with severe acute liver failure. *World J Hepatol* 2019; 11(3): 273-286

**URL:** https://www.wjgnet.com/1948-5182/full/v11/i3/273.htm

**DOI:** https://dx.doi.org/10.4254/wjh.v11.i3.273

**INTRODUCTION**

Severe acute liver failure (SALF) is a complex and rare syndrome characterized by rapid deterioration of liver function, usually in patients without underlying liver disease[1,2]. Management includes intensive and comprehensive supportive care, but the only effective treatment to date is liver transplantation[3].

The xenobiotic thioacetamide (TAA) has been used to induce hepatic damage in animals, and constitutes an effective experimental model to study the mechanisms involved in the pathophysiology of SALF and investigate potential therapies thereof.

Several studies have implicated oxidative stress and inflammation as critical events involved in experimental SALF[4-9].

Reactive oxygen species (ROS) are generated during the process of oxygen metabolism and play several important physiological roles, including signal transduction, defense against microbial pathogens, and gene expression to support cell growth or cell death signaling pathways[5,10]. Reactive nitrogen species (RNS), in turn, are derived from nitric oxide (NO), which is produced *via* inducible nitric oxide synthase (iNOS) activity[5,6]. Because of their unique chemical characteristics, ROS and RNS can trigger lipid peroxidation and cause DNA strand breaks and protein oxidation, resulting in cellular injury. Oxidative and nitrosative stress represents an imbalance in the production and elimination of these reactive species and a decrease in the production of antioxidants[5,11,12].

The antioxidant defense system is essential for cell protection. Antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as non-enzymatic electron receptors such as glutathione (GSH), are affected by oxidative stress conditions[12,13]. The nuclear factor erythroid 2-related factor 2 (Nrf2) is an important regulator of redox balance. Under physiological conditions, Nrf2 is stores in the cytoplasm in inactivated form, bound to Kelch-like ECH-associated protein 1 (Keap1). Under stress conditions, Nrf2 dissociates Keap1 and is translocated to the nucleus, where it promotes expression of cytoprotective target genes, such as NADPH quinone oxidoreductase1 (NQO1), antioxidant enzymes, and phase-II detoxification enzymes such as glutathione S-transferase (GST)[5,14-16].

Inflammation is a key component of several liver diseases. The inflammatory process leads to parenchymal damage, which progresses to fibrosis, liver cancer, and, occasionally, SALF[17]. Metabolites of hepatotoxic drugs bind to a toll-like receptor 4 (TLR4) complex that activates nuclear factor kappa B (NFκB), triggering the production of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6, and modulation of anti-inflammatory cytokines such as IL-10[12,14,17,18]. Furthermore, it can stimulate production of the enzymes cyclooxygenase-2 (COX-2) and iNOS, both of which act as inflammatory mediators[19].

Many isolated compounds have been investigated for their potential to eliminate oxidative stress and mitigate the inflammatory process in liver diseases. Within this context, glutamine (Gln) has been investigated due to its important role in a wide range of metabolic pathways. It is indispensable for nucleotide, glucose, and protein synthesis. It is a precursor of GSH and plays a key role in the immune defense of the gut mucosal barrier, participating in immunoglobulin formation[20,21]. Several studies in humans have shown that Gln modulates the expression of genes related to the activation of pathways involved in several disease states[22-25]. Furthermore, studies conducted in different experimental models have demonstrated beneficial effects of Gln on the rat liver, bowel, and stomach[21,26-30].

Within this context, the present study aimed to evaluate the effect of Gln as an antioxidant and its role in the inflammatory process in an experimental model of IHAG induced by TAA.

**MATERIALS AND METHODS**

***Ethical considerations***

This study was conducted at the Animal Experimentation Unit and the Laboratory of Experimental Hepatology and Gastroenterology, Hospital de Clínicas de Porto Alegre, after approval from the Institutional Animal Care and Use Committee (opinion no. CEUA 15-0175).

Animal handling followed the ethical principles for animal experimentation mandated by current Brazilian legislation (Law no. 11794/2008), the standards of the Brazilian Council for the Control of Animal Experimentation (CONCEA), the State Code for Animal Protection, and established local procedures for the care and use of animals in experimental research.

***Experimental procedures***

Twenty-eight male Wistar rats (mean weight 300 g) were used in this study. During the experiment, the animals were housed in boxes (47 cm × 34 cm × 18 cm) lined with wood shavings, in a 12-h light/dark cycle, and a controlled temperature of 18 to 22 °C. Water and feed were given ad libitum. The animals were randomized in four groups (*n* = 7 each): control (CO), control plus glutamine (CO + G), TAA, and TAA plus glutamine (TAA + G).

IHAG was induced by intraperitoneal administration of two doses of TAA, 400 mg/kg in normal saline solution (0.9% NaCl), with an 8-hour interval between doses[8]. The glutamine-treated groups received intraperitoneal Gln (Sigma Chemical®, St. Louis, MO, United States), 25 mg/kg in 1 mL 0.9% NaCl. The first dose was administered 30 min after the last dose of TAA; the second and third doses of Gln were administered 24 and 36 h, respectively, after the start of the experiment.

At 48 h, the animals were weighed and anesthetized by intraperitoneal injection of a mixture of ketamine hydrochloride (95 mg/kg) and 2% xylazine hydrochloride (8 mg/kg). Blood was then collected from the retro-orbital plexus with a glass capillary tube and placed into a heparin-containing test tube to prevent coagulation.

After blood sampling, animals were euthanized by anesthetic overdose (three times the therapeutic dose, as per CONCEA guidelines)[31]. Upon confirmation of death, the abdominal region was shaved and disinfected, a midline ventral laparotomy was performed, and the liver was removed in sections for storage and subsequent analysis. One liver fragment was submerged in 10% formaldehyde solution for 24 h for histological examination, while another fragment was frozen −80 °C for other analyses.

***Histological examination of hepatic tissue***

Tissue samples were fixed in 10% formalin and embedded in paraffin. The resulting paraffin blocks were then placed in a Leitz® 1512 microtome and cut into sections 3 μm thick. The slides were then dipped in hematoxylin and eosin (HE) for 5 min each and placed in a running water bath. For dehydration, the slides were run through a graded ethanol series, followed by two xylol baths. Finally, coverslips were mounted with Canada balsam. Slides were examined under a light microscope coupled to a digital camera. Images were captured using Image-Plus software (Media Cybernetics®, Bethesda, United States) at a magnification of 200×. Hallmarks of acute liver injury were scored on a scale of 0 to 3, where 0 = normal hepatic tissue; 1 = mild damage with scant inflammatory infiltration; 2 = moderate damage and infiltration; and 3 = severe damage with infiltration and loss of hepatic architecture.

***Spectrophotometric analysis of biochemical parameters***

Hepatic integrity was assessed by measurement of the liver enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) in plasma, using the commercially available Liquiform Labtest® kit (a kinetic spectrophotometric assay). Protein content in liver homogenate was determined by Bradford’s method[32]. Lipid peroxidation was investigated by the thiobarbituric acid-reactive substances (TBARS) method[33]. Levels of GSH were evaluated[34], as well as activity of the antioxidant enzymes catalase (CAT)[35] and glutathione peroxidase (GPx)[36] and of the phase-II detoxification enzyme glutathione S-transferase (GST)[37]. Production of nitric oxide metabolites (NO2/NO3) was measured indirectly by the Griess reaction[38].

***Western blot analysis of protein expression***

Cytoplasmic and nuclear extracts were prepared from liver homogenates[39]. The supernatant fraction was collected, aliquoted, and stored at −80 °C. Protein content was determined by Bradford’s method[32]. Lysed proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes[40,41]. The membranes were then blocked with 5% skim milk in Tris buffer containing 0.05% Tween (TTBS) for 1 hour at room temperature and probed overnight at 4 °C with anti-Nrf2 (57 kDa), anti-Keap1 (69 kDa), anti-NQO1 (31 kDa), anti-SOD (32 kDa), anti-TLR4 (95 to 120 kDa), anti-NFκB (65 kDa), anti-COX-2 (21 kDa), and anti-iNOS (120 kDa) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, United Staes), diluted 1:200 to 1:1000 with TTBS in dehydrated milk at 5%. Primary antibodies were detected with HRP-conjugated anti-rat IgG, anti-rabbit IgG, or anti-goat IgG secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, United States). Protein detection was performed with a commercially available electrochemiluminescence kit (Amersham Pharmacia Biotech, Little Chalfont, Bucks, England)[42]. Density of the specific bands was quantified with imaging densitometry software (Scion Image, Scion Corporation, Frederick, MA, United States).

***Multiplex analysis***

Levels of IL-1, IL-6, IL-10, and TNF-α were measured in hepatic tissue homogenates using a MILLIPLEX™ MAP Rat Cytokine bead-based multiplex assay kit (RCYTO-80K, Millipore, Billerica, MA, United States). The MILLIPLEX™ MAP method is based on Luminex® xMAP™ technology. All procedures were performed in accordance with manufacturer recommendations. Tissue specimens were diluted 1:5 in sample diluent and incubated in duplicate overnight with TNF-α, IL-1, IL-6, and IL-10 capture beads. The beads were subsequently washed and incubated for 2 h with biotin-conjugated detection antibody, and then for 30 min with streptavidin-phycoerythrin. Bead fluorescence was read in a Luminex 100 IS Multiplex BioAssay analyzer. Cytokine concentrations were determined from these readings using four standard curves. Results were expressed as pg/mL.

***Statistical analysis***

Quantitative data were expressed as mean ± SE. Groups were compared by one-way analysis of variance (ANOVA). Differences in means were located by the Student–Newman–Keuls procedure. Data were analyzed in program GraphPad InsTat 3.1, and significance was accepted at *P* < 0.05. The statistical methods of this study were reviewed by Ceres Andréia Vieira Oliveira, from the Regional Statistical Council of Rio Grande do Sul and Santa Catarina, Brazil.

**RESULTS**

***Histopathological analysis***

On histological examination of H&E-stained slides at 200× magnification (Figure 1), disruption of the hepatic parenchyma was observed in the TAA group, with inflammatory infiltration, massive necrosis, and ballooning; none of these features occurred in the CO or CO + G groups. Photomicrographs of liver tissue from rats in the TAA + G group show regeneration of the hepatic parenchyma, with a decrease in inflammatory infiltration and a substantial reduction in ballooning and spotty necrosis.

***Assessment of hepatic cellular integrity***

Liver function tests (Table 1) showed increased levels of liver enzymes in TAA group animals, which decreased significantly when Gln was administered (*P* < 0.05).

***Assessment of oxidative stress***

Assessment of lipid peroxidation by the TBARS method (Figure 2) revealed a significant increase in the TAA group in relation to the CO and CO + G groups (*P* < 0.001). Again, significant reductions were observed in the TAA + G group (to which Gln was administered) as compared with the TAA group (*P* < 0.001).

Nuclear expression of Nrf2 (Figure 3A) was decreased in the TAA group as compared with the CO and CO + G groups (*P* < 0.01), and increased in the TAA + G group as compared with the TAA group (*P* < 0.05). Conversely, expression of the inhibitory cytoplasmic protein Keap1 (Figure 3B) was increased in the TAA group as compared to both control groups (*P* < 0.001) and significantly reduced in the TAA + G group when compared to the TAA group (*P*<0.01).

Expression of both NQO1 (Figure 4A) and SOD (Figure 4B) was decreased in the TAA group compared to the CO and CO + G groups (*P*<0.001 and *P* < 0.05, respectively) and increased in the TAA + G group as compared to the TAA group (*P*<0.01).

GSH levels (Figure 5) were statistically lower in the TAA group than in both control groups (*P* < 0.01), but increased significantly in the TAA + G group (*P* < 0.01).

Table 2 shows the findings of analysis of activity of the antioxidant enzymes CAT and GPx and the detoxification enzyme GST. GPx enzyme activity was increased in the TAA group as compared with the CO and CO + G groups (*P* < 0.001), and decreased in the Gln-treated group as compared with the TAA group (*P* < 0.01). CAT activity exhibited the inverse behavior; it was lower in the TAA group than in the control groups (*P* < 0.01) and higher in the TAA + G group than in the TAA group (*P* < 0.01). GST activity increased in the TAA group (*P* < 0.001) and decreased in the Gln-treated group (*P* < 0.001), which is consistent with its detoxifying role.

***Assessment of the inflammatory process***

Cytoplasmic expression of TLR4 (Figure 6A) and nuclear expression of NFκB (Figure 6B) were significantly increased in the TAA group as compared with control groups (*P* < 0.001), and significantly decreased in the TAA + G group *vs* the TAA group (*P* < 0.001).

Levels of the proinflammatory cytokines IL-1β, IL-6, and TNFα (Table 3) were higher in the TAA group than in both control groups, CO and CO + G (*P* < 0.001). These levels decreased significantly in the TAA + G group *vs* the TAA group (*P* < 0.01). In contrast, levels of the anti-inflammatory cytokine IL-10 were decreased in the TAA group in relation to the CO and CO + G groups (*P* < 0.001) and increased in the TAA + G group *vs* the TAA group (*P* < 0.001).

Expression of both COX-2 (Figure 7A) and iNOS (Figure 7B) was increased in the TAA group compared to the CO and CO + G groups (*P* < 0.001) and decreased in the TAA + G group as compared to the TAA group (*P* < 0.01).

Assessment of NO levels through their metabolites (nitrites and nitrates) (Figure 8) revealed a significant increase in the TAA group *vs* the CO and CO + G groups (*P* < 0.001) and a significant decrease in the TAA + G group as compared with the TAA group (*P* < 0.05).

**DISCUSSION**

SALF is a syndrome that causes a marked decline in hepatocyte function, leading to multiple organ failure and leads to an extremely high mortality rate due to several etiologies: drug-induced liver injury (DILI), xenobiotics, viral hepatitis, diseases metabolic, vascular and autoimmune. In many situations the cause remains unknown. The therapeutic armamentarium available to prevent or treat SALF is still very limited[18]. Studies using TAA as an inducer of tissue damage have shown that this xenobiotic leads to different degrees of liver injury depending on the dose and timing of administration. This study aimed to evaluate the damage caused by acute administration of TAA in rats and assess the effects of Gln on the Nrf2-mediated antioxidant pathway and on chemical mediators of inflammation.

We observed extensive destruction of the hepatic parenchyma with necrosis, spotty hemorrhaging, leukocyte infiltration, and ballooning in the group of animals administered TAA. These findings are consistent with previous studies that reported hepatic tissue damage in experimental models using TAA[43-45]. In the present study, Gln was able to mitigate changes in the parameters of interest, thus restoring the hepatic parenchyma. Sellmann et al. showed that Gln contributed to a reduction of inflammatory infiltration in the livers of mice with non-alcoholic steatohepatitis induced by a liquid Western-style diet (WSD)[28]. Hartmann et al. found that Gln reduced hemorrhagic spots, necrosis, and inflammatory infiltration in the liver of rats subjected to intestinal ischemia–reperfusion injury[21].

Similar results were found on analysis of hepatic cell integrity. Gln reduced serum levels of AST, ALT, and ALP, while significantly increased levels of these enzymes were found in animals in the TAA group, suggesting massive hepatic impairment after exposure to the xenobiotic. In other studies, Gln was also able to decrease serum levels of these enzymes, thus corroborating our findings[7,14,46].

We also observed an increase in TBARS levels in the livers of animals in the TAA group, which is indicative of increased lipid peroxidation. Other authors found similar increases in TBARS in studies that used TAA to induce liver damage[6,7,43]. Again, Gln administration was able to reduce these levels in our animals, corroborating the findings of several other studies that have demonstrated its protective effect in different experimental models[21,26,47].

Cellular stress mediators activate Nrf2, which is translocated to the nucleus and binds to DNA through a region known as the antioxidant response element (ARE). This promotes expression of cytoprotective target genes, including antioxidant and detoxification enzymes[5]. In the present study, Gln promoted increased nuclear expression of Nrf2, whereas cytoplasmic expression of its inhibitory protein Keap1 was downregulated. Gln also promoted increased expression of the NQO1 protein and the antioxidant enzyme SOD. Similar results were reported in a study that evaluated expression of the Nrf2/Keap1 antioxidant pathway, NQO1, and SOD in the liver of rats subjected to intestinal ischemia and reperfusion[14].

GSH is considered an important marker of the antioxidant defenses of the cell. High doses of TAA lead to liver damage because it is biotransformed into a rapidly reacting metabolite that causes an imbalance of the glutathione redox cycle[44]. In this study, Gln was able to increase GSH levels in liver tissue, demonstrating its protective role. Similar results were observed by Cruzat et al., who studied the antioxidant effects of Gln in endotoxemic animals[47].

The first line of antioxidant defense is represented by the antioxidative enzymes, such as CAT and SOD. In this study, CAT activity was decreased in the TAA group in relation to both control groups. This reduction may reflect the redox imbalance induced by stress resulting from xenobiotic administration. Conversely, CAT activity was increased in the group which received Gln treatment. Other studies using TAA-induced liver damage models have demonstrated increased CAT activity in animals treated with berberine and α-lipoic acid[19,46].

GPx enzyme activity was increased in the TAA group and decreased in the Gln-treated group. The proper balance of antioxidative enzyme activity plays an important role in cellular protection against oxidative stress. GPx acts in an attempt to reduce molecules with oxidative potential, especially hydrogen peroxide and hydroperoxides, which may explain its increased activity in the group of animals that received TAA. Similar results regarding GPx activity were reported in other studies that used the experimental model of TAA-induced SALF and evaluated the antioxidant action of vitamin E and melatonin[6,7].

GST is an important cellular detoxification enzyme that works in tandem with GSH to remove toxic metabolites. In this study, GST was increased in the TAA group, and Gln treatment was able to reduce its activity. Other authors have reported similar increases in GST in other hepatotoxicity models[7,48]. The protective action of Gln in this experimental model may be due to the fact that it is a precursor for GSH synthesis.

The link between oxidative stress and inflammation has been recognized in many disease states, including those which affect the liver. ROS stimulate signaling molecules such as TLR4 to activate inflammatory mediators, including NFκB, which upregulates the production of inflammatory cytokines (such as IL-1β, IL-6, and TNFα) and other mediators of inflammation (such as iNOS and COX-2)[46].

In this study, expression of TLR4 and NFκB in the TAA group was increased in relation to both control groups. Similar results were reported in another study that evaluated TLR4 signaling pathways in a model of TAA-induced hepatic fibrosis and liver carcinogenesis[49] and in a study that evaluated NFκB activity in an LPS-induced model of SALF[18]. Gln was able to reduce TLR4 and NFκB expression, thus demonstrating its effectiveness in blunting the inflammatory process. A decrease in inflammatory modulators was also observed in other experimental studies that used allopurinol and Gln as treatments[14,50,51].

In the present study, levels of the proinflammatory cytokines IL-1β, IL-6, and TNFα increased while those of the anti-inflammatory cytokine IL-10 declined in animals that received TAA as a hepatotoxicant. Gln reversed the inflammatory process, as demonstrated by a decrease in levels of IL-1β, IL-6, and TNFα and an increase in levels of IL-10 in liver tissue after its administration. A previous study using the TAA model of liver injury also demonstrated an increase in levels of proinflammatory cytokines in animals that developed TAA-induced liver damage[46]. Another study reported a similar anti-inflammatory action of Gln in the liver of animals subjected to experimental endotoxemia[47].

Activation of the TLR4/NFκB pathway promotes COX-2 production. In this study, COX-2 expression was increased in the group that received TAA and decreased in the group that received TAA followed by Gln as treatment. In another study of TAA-induced hepatotoxicity, the authors observed a similar increase in COX-2 expression, followed by decreased expression after treatment with allopurinol[50].

As a hepatotoxicant, TAA may induce production of iNOS and, consequently, NO synthesis, which further increases inflammation in the liver. In this study, we observed overexpression of iNOS and an increase in NO (as measured by levels of its nitrite and nitrate metabolites) in the liver of animals with TAA-induced SALF. Gln was able to reverse these parameters, reducing iNOS expression and nitrite and nitrate levels. In a study using the intestinal ischemia–reperfusion model, the authors observed a similar pattern of iNOS expression and NO levels in the liver of animals which Gln treatment[14].

Gln is an essential amino acid for several cell types, including hepatocytes. The mechanisms underlying the protective effects promoted by Gln include the antioxidant of GSH, which is dependent on a supply of glutamate—this, in turn, is synthesized from Gln. In addition, its protective role in the inflammatory process has been widely reported[47]. Gln can attenuate oxidative stress and inflammation, consequently protecting against a variety of mechanisms of cell and tissue injury. In humans, Gln supplementation has been used in clinical practice especially in diseases of the gastrointestinal tract with daily doses that can reach 20 g, being administered preferably parentenally.

In conclusion, the results of this experimental study demonstrate that Gln administration had a protective role on the Nrf2-mediated antioxidant pathway and on inflammation activated by the TLR4/NFκB pathway in rats with TAA-induced SALF. As the molecular pathways involved in the pathophysiology of SALF are manifold and complex, further experimental studies are warranted to investigate other potential mechanisms of Gln action in this setting.

**ARTICLE HIGHLIGHTS**

***Research background***

Severe acute liver failure (SALF) is a serious disease that does not have an effective treatment and liver transplantation is the only viable alternative. The mechanisms intrinsic to the pathophysiology of the disease are still not well understood and therefore, experimental studies are of fundamental importance in the attempt to elucidate the mechanisms and therapeutic agents. Glutamine is an amino acid used in the treatment of various diseases of the gastrointestinal tract and has been shown to be promising in previous studies of liver diseases.

***Research motivation***

In a previous study, the authors developed the experimental model of thioacetamide-induced SALF across different times. From the obtained data the best model to be studied was defined. It was evaluated the antioxidant action of glutamine that presented promising data. With the continuity of the research, we evaluated in this work the pathways of oxidative stress and inflammatory process at the molecular level, involved in the SALF. The results of this research are important indicators of the restorative role of glutamine in the SALF experimental model and will certainly provide a basis for a better understanding of the evaluated mechanisms contributing to the continuity of the studies.

***Research objectives***

The objective of this study was to investigate the action of glutamine on parameters of oxidative stress and inflammatory process in the experimental SALF. It is known that such parameters are implicated in the pathophysiology of various diseases. The understanding of the routes studied offers a basis for further studies that may evaluate other pathways involved in the disease, as well as the action of other therapeutic agents.

***Research methods***

To induce SALF in wistar rats the xenobiotic thioacetamide was used. The animals were randomized into different groups. In the treatment groups, the animals received doses of glutamine intraperitoneally. Blood tests were performed to evaluate hepatic integrity through a commercial kit. Liver portions were used for histopathological evaluation through hematoxylin and eosin staining. Techniques based on spectrophotometry were performed through protocols for the analysis of oxidative stress and inflammatory process. Protein expression was performed by Western Blot and cytokine analysis was done using multiplex technology based on magnetic beads through commercial kit.

***Research results***

Glutamine reduced hepatic integrity enzymes and restored the liver of the animals evidenced by decreased necrosis, balloonization and inflammation in the histopathological analysis. In addition, glutamine reduced lipid peroxidation and restored antioxidant enzyme activity. It was evidenced the decrease of the expression of proteins of the oxidative system and of the inflammatory process. Glutamine was able to increase the levels of interleukin 10, an important anti-inflammatory cytokine and also the expression of Nrf2, NQO1 and GSH levels, important proteins of the antioxidant protection system.

***Research conclusions***

When evaluating mechanisms implicated in the experimental SALF, studying parameters of oxidative stress and inflammatory process, it was possible to observe the protective action of glutamine in the liver of the animals. It is possible to confirm with this study that the oxidative stress and the inflammatory process play a primordial role in the progression of the disease, evidenced by the study of the molecular aspects. Glutamine has been shown to be effective by activating the antioxidant system and minimizing damage from the inflammatory process. Therefore, it presents as a viable alternative in the treatment of patients with severe hepatic insufficiency. Still, new studies confirming the efficacy of glutamine are needed so that in the future it may be part of the routine in the medical clinic.

***Research perspectives***

In this study the efficacy of the experimental model proposed by the authors in a previous study was confirmed. The pathophysiological mechanisms involved in SALF are diverse and complex. For further clarification of these mechanisms, other molecular routes should be investigated in an attempt to elucidate the aspects involved. We present the details of the involvement of the oxidative stress and the inflammatory process in this research and we hope that further studies can provide technical and theoretical data for the development of viable and effective strategies in the treatment of patients with SALF.

**ACKNOWLEDGEMENTS**

Funding was provided by Fundo de Incentivo à Pesquisa e Eventos (FIPE) do Hospital de Clínicas de Porto Alegre (HCPA); Universidade Federal do Rio Grande do Sul (UFRGS); Universidade Luterana do Brasil (ULBRA); the Coordination for the Improvement of Higher Education Personnel (CAPES); the National Council for Scientific and Technological Development (CNPq); and the Research Support Foundation of Rio Grande do Sul (FAPERGS). The authors thank Ceres Andréia Vieira Oliveira for her assistance with statistical analysis.

**REFERENCES**

1 **Cardoso LMDF**, Moreira LFP, Pinto MA, Henriques-Pons A, Alves LA. Domino Hepatocyte Transplantation: A Therapeutic Alternative for the Treatment of Acute Liver Failure. *Can J Gastroenterol Hepatol* 2018; **2018**: 2593745 [PMID: 30065914 DOI: 10.1155/2018/2593745]

2 **Scott TR**, Kronsten VT, Hughes RD, Shawcross DL. Pathophysiology of cerebral oedema in acute liver failure. *World J Gastroenterol* 2013; **19**: 9240-9255 [PMID: 24409052 DOI: 10.3748/wjg.v19.i48.9240]

3 **Wu C**, Zhu Y, Yu M. Serum Metabonomics Analysis of Liver Failure Treated by Nonbioartificial Liver Support Systems. *Can J Gastroenterol Hepatol* 2018; **2018**: 2586052 [PMID: 30073154 DOI: 10.1155/2018/2586052]

4 **Li AN**, Li S, Zhang YJ, Xu XR, Chen YM, Li HB. Resources and biological activities of natural polyphenols. *Nutrients* 2014; **6**: 6020-6047 [PMID: 25533011 DOI: 10.3390/nu6126020]

5 **Li S**, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The Role of Oxidative Stress and Antioxidants in Liver Diseases. *Int J Mol Sci* 2015; **16**: 26087-26124 [PMID: 26540040 DOI: 10.3390/ijms161125942]

6 **Miguel FM**, Schemitt EG, Colares JR, Hartmann RM, Morgan-Martins MI, Marroni NP. Action of Vitamin E on Experimental Severe Acute Liver Failure. *Arq Gastroenterol* 2017; **54**: 123-129 [PMID: 28198914 DOI: 10.1590/s0004-2803.201700000-03]

7 **Salvi JO,** Schemitt EG, Colares JR, Hartmann RM, Marroni CA, Marroni NAP. Action of melatonin on severe acute liver failure in rats. *J Pharmacy Biol Sci* 2017; **12**: 62-75 [DOI: 10.9790/3008-1203036275]

8 **Schemitt EG,** Colares JR, Hartmann RM, Morgan-Martins M, Marroni CA, Tunon MJ, Marroni NP. Effect of glutamine on oxidative stress and infammation in a rat model of fulminant hepatic failure. *Nutricion hospitalaria* 2016; **33**: 92

9 **Shen Z**, Wang Y, Su Z, Kou R, Xie K, Song F. Activation of p62-keap1-Nrf2 antioxidant pathway in the early stage of acetaminophen-induced acute liver injury in mice. *Chem Biol Interact* 2018; **282**: 22-28 [PMID: 29331651 DOI: 10.1016/j.cbi.2018.01.008]

10 **Finkel T**, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. *Nature* 2000; **408**: 239-247 [PMID: 11089981 DOI: 10.1038/35041687]

11 **Cichoż-Lach H**, Michalak A. Oxidative stress as a crucial factor in liver diseases. *World J Gastroenterol* 2014; **20**: 8082-8091 [PMID: 25009380 DOI: 10.3748/wjg.v20.i25.8082]

12 **Ajuwon OR,** Marnewick JL, Davids LM. 1`qRooibos (Aspalathus linearis) and its major flavonoids - Potential against oxidative stress-induced conditions. In: Gowder SJT, ed. Basic principles and clinical significance of oxidative stress. *Intech* 2015; 171-218 [DOI: 10.5772/61614]

13 **Valente MJ**, Carvalho F, Bastos Md, de Pinho PG, Carvalho M. Contribution of oxidative metabolism to cocaine-induced liver and kidney damage. *Curr Med Chem* 2012; **19**: 5601-5606 [PMID: 22856659 DOI: 10.2174/092986712803988938]

14 **Hartmann RM**, Licks F, Schemitt EG, Colares JR, do Couto Soares M, Zabot GP, Fillmann HS, Marroni NP. Protective effect of glutamine on the main and adjacent organs damaged by ischemia-reperfusion in rats. *Protoplasma* 2017; **254**: 2155-2168 [PMID: 28382390 DOI: 10.1007/s00709-017-1102-3]

15 **Wang H**, Chen X, Su Y, Paueksakon P, Hu W, Zhang MZ, Harris RC, Blackwell TS, Zent R, Pozzi A. p47(phox) contributes to albuminuria and kidney fibrosis in mice. *Kidney Int* 2015; **87**: 948-962 [PMID: 25565313 DOI: 10.1038/ki.2014.386]

16 **Zhang YK**, Wu KC, Klaassen CD. Genetic activation of Nrf2 protects against fasting-induced oxidative stress in livers of mice. *PLoS One* 2013; **8**: e59122 [PMID: 23527105 DOI: 10.1371/journal.pone.0059122]

17 **Ludwig JM**, Zhang Y, Chamulitrat W, Stremmel W, Pathil A. Anti-inflammatory properties of ursodeoxycholyl lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury. *PLoS One* 2018; **13**: e0197836 [PMID: 29795632 DOI: 10.1371/journal.pone.0197836]

18 **Yin X**, Gong X, Jiang R, Kuang G, Wang B, Zhang L, Xu G, Wan J. Emodin ameliorated lipopolysaccharide-induced fulminant hepatic failure by blockade of TLR4/MD2 complex expression in D-galactosamine-sensitized mice. *Int Immunopharmacol* 2014; **23**: 66-72 [PMID: 25173984 DOI: 10.1016/j.intimp.2014.08.018]

19 **Xia X**, Su C, Fu J, Zhang P, Jiang X, Xu D, Hu L, Song E, Song Y. Role of α-lipoic acid in LPS/d-GalN induced fulminant hepatic failure in mice: studies on oxidative stress, inflammation and apoptosis. *Int Immunopharmacol* 2014; **22**: 293-302 [PMID: 25046589 DOI: 10.1016/j.intimp.2014.07.008]

20 **Chen S**, Xia Y, Zhu G, Yan J, Tan C, Deng B, Deng J, Yin Y, Ren W. Glutamine supplementation improves intestinal cell proliferation and stem cell differentiation in weanling mice. *Food Nutr Res* 2018; **62**: [PMID: 30083086 DOI: 10.29219/fnr.v62.1439]

21 **Hartmann R**, Licks F, Schemitt EG, Colares JR, Da Silva J, Moura RM, Zabot GP, Fillmann HS, Marroni NP. Effect of glutamine on liver injuries induced by intestinal ischemia-reperfusion in rats *Nutr Hosp* 2017; **34**: 548-554 [PMID: 28627188 DOI: 10.20960/nh.643]

22 **Cruzat VF,** Petry ER, Trapegui J. Glutamine: biochemical, metabolic, molecular aspects and supplementation. *Revista Brasileira de Medicina do Esporte* 2009; 15

23 **Curi R**, Lagranha CJ, Doi SQ, Sellitti DF, Procopio J, Pithon-Curi TC, Corless M, Newsholme P. Molecular mechanisms of glutamine action. *J Cell Physiol* 2005; **204**: 392-401 [PMID: 15795900 DOI: 10.1002/jcp.20339]

24 **Liboni KC**, Li N, Scumpia PO, Neu J. Glutamine modulates LPS-induced IL-8 production through IkappaB/NF-kappaB in human fetal and adult intestinal epithelium. *J Nutr* 2005; **135**: 245-251 [PMID: 15671221 DOI: 10.1093/jn/135.2.245]

25 **Ziegler TR**. Glutamine supplementation in cancer patients receiving bone marrow transplantation and high dose chemotherapy. *J Nutr* 2001; **131**: 2578S-84S; discussion 2590S [PMID: 11533316 DOI: 10.1093/jn/131.9.2578S]

26 **Fillmann H**, Kretzmann NA, San-Miguel B, Llesuy S, Marroni N, González-Gallego J, Tuñón MJ. Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. *Toxicology* 2007; **236**: 217-226 [PMID: 17543437 DOI: 10.1016/j.tox.2007.04.012]

27 **Kretzmann NA**, Fillmann H, Mauriz JL, Marroni CA, Marroni N, González-Gallego J, Tuñón MJ. Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis. *Inflamm Bowel Dis* 2008; **14**: 1504-1513 [PMID: 18623154 DOI: 10.1002/ibd.20543]

28 **Sellmann C**, Baumann A, Brandt A, Jin CJ, Nier A, Bergheim I. Oral Supplementation of Glutamine Attenuates the Progression of Nonalcoholic Steatohepatitis in C57BL/6J Mice. *J Nutr* 2017; **147**: 2041-2049 [PMID: 28931589 DOI: 10.3945/jn.117.253815]

29 **Ventura G**, Bortolotti M, Neveux N, Gusmini X, Nakib S, Sarfati G, Cynober L, De Bandt JP. Influence of an ω3-fatty acid-enriched enteral diet with and without added glutamine on the metabolic response to injury in a rat model of prolonged acute catabolism. *Nutrition* 2017; **42**: 75-81 [PMID: 28870483 DOI: 10.1016/j.nut.2017.06.001]

30 **Zabot GP**, Carvalhal GF, Marroni NP, Licks F, Hartmann RM, da Silva VD, Fillmann HS. Glutamine prevents oxidative stress in a model of portal hypertension. *World J Gastroenterol* 2017; **23**: 4529-4537 [PMID: 28740341 DOI: 10.3748/wjg.v23.i25.4529]

31 **Brazil. Ministério da Ciência,** Tecnologia e Inovação. Resolução normativa nº 30, de 2 de fevereiro de 2016. Diretriz brasileira para o cuidado e a utilização de animais em atividades de ensino ou de pesquisa científica – DBCA. [Accessed 28 Sep 2018] Available from: http://www3.icb.usp.br/corpoeditorial/ARQUIVOS/etica-animal/RESOLUCAO\_NORMATIVA\_N\_%2030\_DE\_02\_02\_2016.pdf

32 **Bradford MM**. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; **72**: 248-254 [PMID: 942051]

33 **Buege JA**, Aust SD. Microsomal lipid peroxidation. *Methods Enzymol* 1978; **52**: 302-310 [PMID: 672633]

34 **Beutler E**, Duron O, Kelly BM. Improved method for the determination of blood glutathione. *J Lab Clin Med* 1963; **61**: 882-888 [PMID: 13967893]

35 **Boveris A**, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. *Biochem J* 1973; **134**: 707-716 [PMID: 4749271 DOI: 10.1042/bj1340707]

36 **Guthenberg C**, Mannervik B. Glutathione S-transferase (transferase pi) from human placenta is identical or closely related to glutathione S-transferase (transferase rho) from erythrocytes. *Biochim Biophys Acta* 1981; **661**: 255-260 [PMID: 7295737]

37 **Flohé L**, Günzler WA. Assays of glutathione peroxidase. *Methods Enzymol* 1984; **105**: 114-121 [PMID: 6727659]

38 **Granger DL**, Anstey NM, Miller WC, Weinberg JB. Measuring nitric oxide production in human clinical studies. *Methods Enzymol* 1999; **301**: 49-61 [PMID: 9919553]

39 **Tuñón MJ**, San Miguel B, Crespo I, Jorquera F, Santamaría E, Alvarez M, Prieto J, González-Gallego J. Melatonin attenuates apoptotic liver damage in fulminant hepatic failure induced by the rabbit hemorrhagic disease virus. *J Pineal Res* 2011; **50**: 38-45 [PMID: 20964705 DOI: 10.1111/j.1600-079X.2010.00807.x]

40 **Mauriz JL**, Molpeceres V, García-Mediavilla MV, González P, Barrio JP, González-Gallego J. Melatonin prevents oxidative stress and changes in antioxidant enzyme expression and activity in the liver of aging rats. *J Pineal Res* 2007; **42**: 222-230 [PMID: 17349019 DOI: 10.1111/j.1600-079X.2006.00409.x]

41 **San-Miguel B**, Alvarez M, Culebras JM, González-Gallego J, Tuñón MJ. N-acetyl-cysteine protects liver from apoptotic death in an animal model of fulminant hepatic failure. *Apoptosis* 2006; **11**: 1945-1957 [PMID: 17021698 DOI: 10.1007/s10495-006-0090-0]

42 **Tuñón MJ**, San-Miguel B, Crespo I, Laliena A, Vallejo D, Álvarez M, Prieto J, González-Gallego J. Melatonin treatment reduces endoplasmic reticulum stress and modulates the unfolded protein response in rabbits with lethal fulminant hepatitis of viral origin. *J Pineal Res* 2013; **55**: 221-228 [PMID: 23679826 DOI: 10.1111/jpi.12063]

43 **Salama SM**, Abdulla MA, AlRashdi AS, Ismail S, Alkiyumi SS, Golbabapour S. Hepatoprotective effect of ethanolic extract of Curcuma longa on thioacetamide induced liver cirrhosis in rats. *BMC Complement Altern Med* 2013; **13**: 56 [PMID: 23496995 DOI: 10.1186/1472-6882-13-56]

44 **Sukalingam K**, Ganesan K, Xu B. Protective Effect of Aqueous Extract from the Leaves of Justicia tranquebariesis against Thioacetamide-Induced Oxidative Stress and Hepatic Fibrosis in Rats. *Antioxidants* (Basel) 2018; **7** [PMID: 29932107 DOI: 10.3390/antiox7070078]

45 **Wei DD**, Wang JS, Duan JA, Kong LY. Metabolomic Assessment of Acute Cholestatic Injuries Induced by Thioacetamide and by Bile Duct Ligation, and the Protective Effects of Huang-Lian-Jie-Du-Decoction. *Front Pharmacol* 2018; **9**: 458 [PMID: 29867467 DOI: 10.3389/fphar.2018.00458]

46 **Eissa LA**, Kenawy HI, El-Karef A, Elsherbiny NM, El-Mihi KA. Antioxidant and anti-inflammatory activities of berberine attenuate hepatic fibrosis induced by thioacetamide injection in rats. *Chem Biol Interact* 2018; **294**: 91-100 [PMID: 30138605 DOI: 10.1016/j.cbi.2018.08.016]

47 **Cruzat VF**, Bittencourt A, Scomazzon SP, Leite JS, de Bittencourt PI Jr, Tirapegui J. Oral free and dipeptide forms of glutamine supplementation attenuate oxidative stress and inflammation induced by endotoxemia. *Nutrition* 2014; **30**: 602-611 [PMID: 24698353 DOI: 10.1016/j.nut.2013.10.019]

48 **Zhang Z**, Lv Z, Shao Y, Qiu Q, Zhang W, Duan X, Li Y, Li C. Microsomal glutathione transferase 1 attenuated ROS-induced lipid peroxidation in Apostichopus japonicus. *Dev Comp Immunol* 2017; **73**: 79-87 [PMID: 28302499 DOI: 10.1016/j.dci.2017.03.011]

49 **Seifert L**, Deutsch M, Alothman S, Alqunaibit D, Werba G, Pansari M, Pergamo M, Ochi A, Torres-Hernandez A, Levie E, Tippens D, Greco SH, Tiwari S, Ly NNG, Eisenthal A, van Heerden E, Avanzi A, Barilla R, Zambirinis CP, Rendon M, Daley D, Pachter HL, Hajdu C, Miller G. Dectin-1 Regulates Hepatic Fibrosis and Hepatocarcinogenesis by Suppressing TLR4 Signaling Pathways. *Cell Rep* 2015; **13**: 1909-1921 [PMID: 26655905 DOI: 10.1016/j.celrep.2015.10.058]

50 **Demirel U**, Yalniz M, Aygün C, Orhan C, Tuzcu M, Sahin K, Ozercan IH, Bahçecioğlu IH. Allopurinol ameliorates thioacetamide-induced acute liver failure by regulating cellular redox-sensitive transcription factors in rats. *Inflammation* 2012; **35**: 1549-1557 [PMID: 22535497 DOI: 10.1007/s10753-012-9470-5]

51 **Raizel R**, Leite JS, Hypólito TM, Coqueiro AY, Newsholme P, Cruzat VF, Tirapegui J. Determination of the anti-inflammatory and cytoprotective effects of l-glutamine and l-alanine, or dipeptide, supplementation in rats submitted to resistance exercise. *Br J Nutr* 2016; **116**: 470-479 [PMID: 27215379 DOI: 10.1017/S0007114516001999]

**P-Reviewer:** El-Bendary M, Kao JT, Sridharan G **S-Editor:** Cui LJ **L-Editor:** A **E-Editor:** Zhang YL

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Brazil

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Effect of glutamine on hepatic integrity levels in rats with severe acute liver failure**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enzyme | CO | CO + G | TAA | TAA + G |
| AST (U/L) | 38.25 ± 5.82 | 44.96 ± 5.69 | 623.58 ± 51.66a | 269.38 ± 33.26c |
| ALT (U/L) | 29.65 ± 4.65 | 33.45 ± 3.12 | 326.27 ± 33.65a | 66.54 ± 9.49c |
| ALP (U/L) | 21.36 ± 2.69 | 19.64 ± 0.96 | 71.49 ± 4.22a | 29.64 ± 3.33c |

a*P* < 0.05, TAA, CO *vs* CO + G; c*P* < 0.05, TAA + G *vs* TAA. Values expressed as mean ± SE. CO: Control; G: Glutamine; TAA: Thioacetamide; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase.

**Table 2 Effect of glutamine on enzyme activity of catalase, glutathione peroxidase, and glutathione S-transferase in rats with experimental severe acute** **liver failure**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enzyme | CO | CO + G | TAA | TAA + G |
| catalase  (ρmol/min/mg prot) | 0.47 ± 0.04 | 0.51 ± 0.02 | 0.24 ± 0.06b | 0.38 ± 0.03d |
| glutathione peroxidase  (nmol/min/mg prot) | 0.31 ± 0.05 | 0.36 ± 0.07 | 0.99 ± 0.11c | 0.72 ± 0.09d |
| glutathione S-transferase  (µmol/min/mg prot) | 231.64 ± 11.25 | 249.65 ± 26.38 | 769.75 ± 55.69c | 326.81 ± 41.25d |

b*P* < 0.01, c*P* < 0.001, TAA, CO *vs* CO + G;  d*P* < 0.001, TAA + G *vs* TAA. Values expressed as mean ± SE. CO: Control; G: Glutamine; TAA: Thioacetamide.

**Table 3 Effect of glutamine on levels of proinflammatory cytokines in the liver of rats with experimental severe acute liver failure**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cytokine | **CO** | **CO + G** | **TAA** | **TAA + G** |
| IL-1β (pg/mL) | 61.10 ± 1.81 | 62.19 ± 1.32 | 465.96 ± 15.90a | 104.69 ± 8.57b |
| IL-6 (pg/mL) | 73.22 ± 0.98 | 78.21 ± 0.88 | 359.40 ± 12.62a | 155.93 ± 6.93b |
| IL-10 (pg/mL) | 145.69 ± 0.99 | 136.25 ± 1.23 | 58.28 ± 4.55a | 99.25 ± 3.11b |
| TNF-α (pg/mL) | 0.68 ± 0.23 | 0.71 ± 0.25 | 2.98 ± 0.64a | 1.45 ± 0.41b |


b*P* < 0.001, TAA, CO *vs* CO + G; d*P* < 0.01, TAA + G *vs* TAA. Values expressed as mean ± SE. CO: Control; G: Glutamine; TAA: Thioacetamide.



d


b

**Figure 1** **Effect of glutamine on liver injury in animals exposed to an experimental model of severe acute liver failure.** Representative photomicrographs; original magnification, 200 ×. Hematoxylin and eosin (HE) stain.In the Thioacetamide (TAA) group, there is visible disruption of the hepatic parenchymal architecture, with inflammatory infiltration, hemorrhage, ballooning, and massive necrosis. The glutamine-treated group (TAA + G) exhibits a reduction of these parameters and restructuring of the hepatic parenchyma. There were no visible tissue changes in the CO and CO + G groups. CO: Control; G: Glutamine; TAA: Thioacetamide. If: Inflammatory infiltrate; h: Hemorrhage; b: Ballooning; n: Necrosis. Values expressed as mean ± SE. b*P* < 0.001, TAA group *vs* groups CO and CO + G; d*P* < 0.01, TAA + G group *vs* the TAA group.



d

**Figure 2** **Assessment of lipid peroxidation in the liver of rats with severe acute liver failure.** Values expressed as mean ± standard error. a*P* < 0.05 TAA group *vs* groups CO and CO + G; d*P* < 0.01 TAA + G group *vs* the TAA group. CO: Control; G: Glutamine; TAA: Thioacetamide.




h

f

c

b

**Figure 3** **Effect of glutamine in experimental severe acute liver failure.** Western blot analysis of protein expression of (A) Nrf2 and (B) Keap1. Values expressed as mean ± standard error. b*P* < 0.01 TAA group *vs* groups CO and CO + G; c*P* < 0.05 TAA + G group *vs* the TAA group; f*P* < 0.001 TAA group *vs* groups CO and CO + G. h*P*< 0.01 TAA + G group *vs* the TAA group. CO: Control; G: Glutamine; TAA: Thioacetamide.




d

d

a

b


**Figure 4** **Effect of glutamine in experimental severe acute liver failure.** Western blot analysis of protein expression of (A) NQO1 and (B) SOD. Values expressed as mean ± SE. a*P* < 0.05 TAA group *vs* groups CO and CO + G. b*P* < 0.01 TAA group *vs* groups CO and CO + G; d*P* < 0.01 TAA + G group *vs* the TAA group. CO: Control; G: Glutamine; TAA: Thioacetamide.



d

b

**Figure 5 Assessment of glutathione (GSH) levels in the liver of rats treated with glutamine after induction of severe acute liver failure.** Values expressed as mean ± standard error. b*P* < 0.001 TAA group *vs* groups CO and CO + G; d*P* < 0.01 TAA + G group *vs* the TAA group. CO: Control; G: Glutamine; TAA: Thioacetamide.




d

d

b

b

**Figure 6** **Effect of glutamine in experimental severe acute liver failure.** Western blot analysis of protein expression of (A) TLR4 and (B) NFκB. Values expressed as mean ± SE. b*P* < 0.001 TAA group *vs* groups CO and CO + G; d*P* < 0.001 TAA + G group *vs* the TAA group. CO: Control; G: Glutamine; TAA: Thioacetamide.




d

d

b

b

**Figure 7** **Effect of glutamine in experimental severe acute liver failure.** Western blot analysis of protein expression of A: iNOS and B: COX-2. Values expressed as mean ± SE. b*P* < 0.001 TAA group *vs* groups CO and CO + G; d*P* < 0.01 TAA + G group *vs* the TAA group. CO: Control; G: Glutamine; TAA: Thioacetamide.



c

b

**Figure 8 Effect of glutamine on levels of nitric oxide metabolites (nitrites and nitrates) in the liver of rats with severe acute liver failure.** Values expressed as mean ± se. b*P* < 0.001, TAA group *vs* groups CO and CO + G; c*P* < 0.05, TAA + G group *vs* the TAA group. CO: Control; G: Glutamine; TAA: Thioacetamide.